132 related articles for article (PubMed ID: 11068747)
1. Use of proteasome inhibitors to examine processing of antigens for major histocompatibility complex class I presentation.
Antón LC; Bennink JR; Yewdell JW
Methods Mol Biol; 2001; 156():17-31. PubMed ID: 11068747
[No Abstract] [Full Text] [Related]
2. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors.
Luckey CJ; Marto JA; Partridge M; Hall E; White FM; Lippolis JD; Shabanowitz J; Hunt DF; Engelhard VH
J Immunol; 2001 Aug; 167(3):1212-21. PubMed ID: 11466336
[TBL] [Abstract][Full Text] [Related]
3. The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen.
Yang B; Hahn YS; Hahn CS; Braciale TJ
J Exp Med; 1996 Apr; 183(4):1545-52. PubMed ID: 8666912
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
5. Antigen processing. Peptides and the proteasome.
Howard JC; Seelig A
Nature; 1993 Sep; 365(6443):211-2. PubMed ID: 8371776
[No Abstract] [Full Text] [Related]
6. Proteases, proteases and proteases for presentation.
Herberts C; Reits E; Neefjes J
Nat Immunol; 2003 Apr; 4(4):306-8. PubMed ID: 12660727
[No Abstract] [Full Text] [Related]
7. Role of proteasomes in antigen presentation.
Gaczynska M; Rock KL; Goldberg AL
Enzyme Protein; 1993; 47(4-6):354-69. PubMed ID: 7697133
[TBL] [Abstract][Full Text] [Related]
8. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
López D; Gil-Torregrosa BC; Bergmann C; Del Val M
J Immunol; 2000 May; 164(10):5070-7. PubMed ID: 10799863
[TBL] [Abstract][Full Text] [Related]
9. A proteolytic system that compensates for loss of proteasome function.
Glas R; Bogyo M; McMaster JS; Gaczynska M; Ploegh HL
Nature; 1998 Apr; 392(6676):618-22. PubMed ID: 9560160
[TBL] [Abstract][Full Text] [Related]
10. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome.
Hughes EA; Hammond C; Cresswell P
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1896-901. PubMed ID: 9050876
[TBL] [Abstract][Full Text] [Related]
11. Antigenicity and immunogenicity of an intracellular delivery system of major histocompatibility complex class I epitopes that bypasses proteasome processing.
Tirosh B; Fridkin M; Tzehoval E; Vadai E; Lemonnier FA; Eisenbach L
J Immunother; 2000; 23(6):622-30. PubMed ID: 11186150
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors and antigen presentation.
Bogyo M; Gaczynska M; Ploegh HL
Biopolymers; 1997; 43(4):269-80. PubMed ID: 9316392
[TBL] [Abstract][Full Text] [Related]
13. Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E.
Bland FA; Lemberg MK; McMichael AJ; Martoglio B; Braud VM
J Biol Chem; 2003 Sep; 278(36):33747-52. PubMed ID: 12821659
[TBL] [Abstract][Full Text] [Related]
14. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading.
Benham AM; Grommé M; Neefjes J
J Immunol; 1998 Jul; 161(1):83-9. PubMed ID: 9647210
[TBL] [Abstract][Full Text] [Related]
15. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.
Momburg F; Ortiz-Navarrete V; Neefjes J; Goulmy E; van de Wal Y; Spits H; Powis SJ; Butcher GW; Howard JC; Walden P
Nature; 1992 Nov; 360(6400):174-7. PubMed ID: 1299222
[TBL] [Abstract][Full Text] [Related]
16. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K; de Giuli R; Schmidtke G; Kostka S; van den Broek M; Kim KB; Crews CM; Kraft R; Groettrup M
J Immunol; 2000 Jun; 164(12):6147-57. PubMed ID: 10843664
[TBL] [Abstract][Full Text] [Related]
17. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
Goletz TJ; Klimpel KR; Arora N; Leppla SH; Keith JM; Berzofsky JA
Proc Natl Acad Sci U S A; 1997 Oct; 94(22):12059-64. PubMed ID: 9342362
[TBL] [Abstract][Full Text] [Related]
18. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.
Seifert U; Marañón C; Shmueli A; Desoutter JF; Wesoloski L; Janek K; Henklein P; Diescher S; Andrieu M; de la Salle H; Weinschenk T; Schild H; Laderach D; Galy A; Haas G; Kloetzel PM; Reiss Y; Hosmalin A
Nat Immunol; 2003 Apr; 4(4):375-9. PubMed ID: 12598896
[TBL] [Abstract][Full Text] [Related]
19. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.
Wiertz EJ; Jones TR; Sun L; Bogyo M; Geuze HJ; Ploegh HL
Cell; 1996 Mar; 84(5):769-79. PubMed ID: 8625414
[TBL] [Abstract][Full Text] [Related]
20. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.
Wu Y; Kipps TJ
J Immunol; 1997 Dec; 159(12):6037-43. PubMed ID: 9550402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
